The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data

Napolitano, Maddalena; Fabbrocini, Gabriella; Ruggiero, Angelo; Marino, Vincenzo; Nocerino, Mariateresa; Patruno, Cataldo

doi:10.2147/dddt.s240866

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 , 13 , 27 , 30 , 34 , 35 These changes were also registered in a phase IIb trial, which included adult patients suffering from moderate-to-severe forms of AD, and also reporting better results for the 200 mg per dose oral abrocitinib, for all patient-reported outcomes. 30 , 33 , 35 …”

Section: Resultsmentioning

confidence: 99%

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives

Niculeț¹,

Bobeică²,

Ștefanopol³

et al. 2022

TCRM

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with high prevalence and a complex pathophysiology. This relapsing and remitting skin disorder has many negative consequences on the patient’s quality of life and that of his family. Until now, moderate-to-severe AD treatment was a symptomatic one, using skin emollients, topical corticosteroids, phototherapy, antihistamines and systemic drugs – immune suppressants and other systemic treatments (dupilumab). Starting from 2021, abrocitinib, a Janus kinase-1 inhibitor, was approved for the treatment of moderate-to-severe cases of AD in Europe, in adults. Multiple phase three studies (JADE MONO-1 [NCT03349060]; JADE MONO-2 [NCT03575871]; JADE TEEN [NCT03796676]; JADE COMPARE; GOODERHAM; JADE EXTEND) have yielded positive results in adults and adolescents suffering from this disease, with efficacy, a good tolerance, safe profile, and with generally mild side effects. The positive results were obtained even starting from the first stages of the oral drug administration. The low frequency of side effects and the advantage of having an orally administered medication makes abrocitinib an important additional tool for the treatment of moderate-to-severe forms of AD.

show abstract

Section: Resultsmentioning

confidence: 99%

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives

Niculeț¹,

Bobeică²,

Ștefanopol³

et al. 2022

TCRM

View full text Add to dashboard Cite

show abstract

“…Abrocitinib, a small-molecule inhibitor of JAK1, has been approved for the treatment of moderate-to-severe atopic dermatitis ( 10 , 11 ). As mentioned in the reviewed paper, phase III clinical trials have demonstrated the effectiveness of abrocitinib in the treatment of moderate-to-severe atopic dermatitis ( 12 ).…”

Section: Discussionmentioning

confidence: 99%

JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series

Xu,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundSteroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.ObjectiveTo observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.MethodsFour Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea.ResultsAbrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed.ConclusionThe JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea.

show abstract

“…284,285,287,[528][529][530] Furthermore, the rapid improvement of pruritus produced by abrocitinib supports treatment compliance, which further validates the safety and tolerability of abrocitinib in patients with moderate-to-severe AD. 531 Abrocitinib has manageable safety, and its common adverse events include nausea, headache, acne and reduced platelet counts. 532,533 Therefore, its benefit-to-harm ratio needs to be thoroughly investigated before it can be used for the long-term treatment of AD.…”

Section: (Covid-19mentioning

confidence: 99%

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Xue

Yao

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment. Various cytokines, interferons, growth factors, and other specific molecules activate JAK-STAT signaling to drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy. Dysregulated JAK-STAT signaling and related genetic mutations are strongly associated with immune activation and cancer progression. Insights into the structures and functions of the JAK-STAT pathway have led to the development and approval of diverse drugs for the clinical treatment of diseases. Currently, drugs have been developed to mainly target the JAK-STAT pathway and are commonly divided into three subtypes: cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors. And novel agents also continue to be developed and tested in preclinical and clinical studies. The effectiveness and safety of each kind of drug also warrant further scientific trials before put into being clinical applications. Here, we review the current understanding of the fundamental composition and function of the JAK-STAT signaling pathway. We also discuss advancements in the understanding of JAK-STAT–related pathogenic mechanisms; targeted JAK-STAT therapies for various diseases, especially immune disorders, and cancers; newly developed JAK inhibitors; and current challenges and directions in the field.

show abstract

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data

Cited by 7 publications

References 25 publications

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives

JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Contact Info

Product

Resources

About